Mesoblast, which is developing regenerative medicine based on adult stem cells, filed and set terms on Monday with the SEC to raise up to $70 million in an initial public offering.
The Melbourne, Australia-based company, which was founded in 2004 and booked $35 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol MESO. Mesoblast filed confidentially on June 26, 2015. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
